EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, US Stem Cell's enterprise value is $9.01 Mil.
US Stem Cell's EBITDA for the trailing twelve months (TTM) ended in Dec. 2022 was $-2.17 Mil. Therefore, US Stem Cell's EV-to-EBITDA for today is -4.15.
The historical rank and industry rank for US Stem Cell's EV-to-EBITDA or its related term are showing as below:
USRM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.15 Med: 0 Max: 0
Current: -4.15
USRM's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.2
vs USRM: -4.15
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
US Stem Cell EV-to-EBITDA Historical Data
The historical data trend for US Stem Cell's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of US Stem Cell's EV-to-EBITDA
For the Biotechnology subindustry, US Stem Cell's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
US Stem Cell's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, US Stem Cell's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where US Stem Cell's EV-to-EBITDA falls into.
US Stem Cell EV-to-EBITDA Calculation
US Stem Cell's EV-to-EBITDA for today is calculated as:
US Stem Cell's current Enterprise Value is $9.01 Mil.
US Stem Cell's EBITDA for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
US Stem Cell (OTCPK:USRM) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
US Stem Cell's PE Ratio for today is calculated as:
US Stem Cell's share price for today is $0.0001.
US Stem Cell's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.005.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of US Stem Cell's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
USRM has been successfully added to your 